0
USD ▼
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Transarterial Chemoembolization Market by Drug Type, Indication, Procedure Type, End-User - Global Forecast to 2030- Product Image
Transarterial Chemoembolization Market by Drug Type, Indication, Procedure Type, End-User - Global Forecast to 2030- Product Image
Sale

Transarterial Chemoembolization Market by Drug Type, Indication, Procedure Type, End-User - Global Forecast to 2030

  • PDF Icon

    Report

  • 197 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6085527
UP TO EUR$697USDGBP OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The transarterial chemoembolization (TACE) market presents senior healthcare executives with a strategic opportunity. Evolving clinical practices, supply chain realignments, and technology investments are all shaping this specialized segment, where advanced localized therapies drive both patient outcomes and competitive advantage.

Market Snapshot: Transarterial Chemoembolization Market Overview

The transarterial chemoembolization market grew from USD 1.57 billion in 2024 to USD 1.66 billion in 2025. It is expected to continue growing at a CAGR of 5.75%, reaching USD 2.20 billion by 2030. These trends reflect rising adoption rates for minimally invasive therapies in oncology, fueled by technological refinements in embolic devices and imaging. As practitioners increasingly favor targeted interventions, market stakeholders are responding with innovative solutions that address a broader range of solid tumor indications.

Scope & Segmentation

This research delivers in-depth analysis and actionable insights into all critical segments and regions relevant to the transarterial chemoembolization market. Detailed coverage includes:

  • Drug Type: Focused on Cisplatin and Doxorubicin.
  • Indication: Including Breast Cancer, Liver Cancer, and Lung Cancer applications.
  • Procedure Type: Spanning Conventional TACE and Drug-Eluting Beads, addressing diverse therapeutic settings.
  • End-User: Covering Ambulatory Surgical Centers, Hospitals, and Specialty Clinics, reflecting varied clinical workflows and operational priorities.
  • Regions: Comprehensive analysis spans the Americas (with specific focus on major U.S. states and leading LATAM economies), Europe, Middle East & Africa (across key Western, Central, and emerging markets), and Asia-Pacific (major countries and dynamic sub-markets).
  • Companies: Review of market activity by AdvaCare Pharma, Cadila Healthcare Limited, Dr. Reddy’s Laboratories Ltd., Johnson & Johnson Services, Inc., LGM Pharma, MicroBiopharm Japan Co., Ltd., Novartis AG, Pfizer Inc., Veranova, L.P., and WG Critical Care, LLC.

Key Takeaways for Senior Decision-Makers

  • Advanced bead technologies and optimized catheters are accelerating procedural efficiency, attracting clinician interest in settings focused on high-throughput and precision.
  • Patient-centric care models are elevating the importance of post-procedural quality-of-life metrics, prompting providers to realign procurement and care standards in response.
  • The integration of artificial intelligence and image-guided delivery systems enables personalized treatment planning, helping multidisciplinary teams optimize case selection and dosing strategies.
  • Ambulatory surgical centers and specialty clinics are leading the adoption of new protocols, leveraging operational agility to offer differentiated services and deepen patient engagement.
  • Collaborative partnerships—spanning device companies, biopharma, and academic centers—are driving rapid translation of scientific advances to clinical use, maintaining ongoing innovation momentum.
  • Vertical integration efforts are reshaping competitive dynamics, with some players combining device, drug, and software capabilities to build end-to-end TACE solution portfolios.

Tariff Impact: Strategic Adjustments in TACE Procurement

New U.S. tariff policies scheduled for implementation in 2025 are compelling manufacturers and providers to revisit supply chain and sourcing strategies for chemoembolization-related devices and materials. Increased duties on contrast media, catheters, and beads drive cost pressures, resulting in the localization of manufacturing operations and new contract arrangements with domestic partners. Healthcare providers are mitigating exposure through bundled procurement and tighter vendor negotiations, maintaining clinical quality amid evolving trade regulations. These shifts are also encouraging material innovation and streamlined manufacturing approaches to sustain margin and resilience.

Methodology & Data Sources

This report employs a multi-tiered research approach, blending exhaustive analysis of peer-reviewed studies, regulatory filings, and patent databases with in-depth interviews involving clinical and industry experts. Primary data collection spans diverse healthcare environments, while quantitative validations ensure reliability through established cross-tabulation and review protocols.

Why This Report Matters

  • Delivers a comprehensive evaluation of emerging trends, enabling C-suite leaders to benchmark investments and product development against market realities.
  • Equips executive teams with insight into tariff and regulatory changes, enhancing preparedness for supply chain and pricing shifts.
  • Guides informed strategy by surfacing competitive intelligence and collaborative opportunities across global markets.

Conclusion

The transarterial chemoembolization market is evolving to meet rising challenges and capture new opportunities through technology, partnerships, and adaptive strategies. Senior leaders who align innovation with operational resilience are best positioned to advance care and outperform in this rapidly changing field.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Transarterial Chemoembolization Market, by Drug Type
8.1. Introduction
8.2. Cisplatin
8.3. Doxorubicin
9. Transarterial Chemoembolization Market, by Indication
9.1. Introduction
9.2. Breast Cancer
9.3. Liver Cancer
9.4. Lung Cancer
10. Transarterial Chemoembolization Market, by Procedure Type
10.1. Introduction
10.2. Conventional TACE
10.3. Drug-Eluting Beads
11. Transarterial Chemoembolization Market, by End-User
11.1. Introduction
11.2. Ambulatory Surgical Centers
11.3. Hospitals
11.4. Specialty Clinics
12. Americas Transarterial Chemoembolization Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Transarterial Chemoembolization Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Transarterial Chemoembolization Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. AdvaCare Pharma
15.3.2. Cadila Healthcare Limited
15.3.3. Dr. Reddy’s Laboratories Ltd.
15.3.4. Johnson & Johnson Services, Inc.
15.3.5. LGM Pharma
15.3.6. MicroBiopharm Japan Co., Ltd.
15.3.7. Novartis AG
15.3.8. Pfizer Inc.
15.3.9. Veranova, L.P.
15.3.10. WG Critical Care, LLC
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. TRANSARTERIAL CHEMOEMBOLIZATION MARKET MULTI-CURRENCY
FIGURE 2. TRANSARTERIAL CHEMOEMBOLIZATION MARKET MULTI-LANGUAGE
FIGURE 3. TRANSARTERIAL CHEMOEMBOLIZATION MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY PROCEDURE TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY PROCEDURE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. TRANSARTERIAL CHEMOEMBOLIZATION MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. TRANSARTERIAL CHEMOEMBOLIZATION MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. TRANSARTERIAL CHEMOEMBOLIZATION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY CISPLATIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DOXORUBICIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY CONVENTIONAL TACE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DRUG-ELUTING BEADS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 25. UNITED STATES TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 26. UNITED STATES TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 27. UNITED STATES TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
TABLE 28. UNITED STATES TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 29. UNITED STATES TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 30. CANADA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 31. CANADA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 32. CANADA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
TABLE 33. CANADA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 34. MEXICO TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 35. MEXICO TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 36. MEXICO TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
TABLE 37. MEXICO TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 38. BRAZIL TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 39. BRAZIL TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 42. ARGENTINA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 46. EUROPE, MIDDLE EAST & AFRICA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 47. EUROPE, MIDDLE EAST & AFRICA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 48. EUROPE, MIDDLE EAST & AFRICA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
TABLE 49. EUROPE, MIDDLE EAST & AFRICA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 50. EUROPE, MIDDLE EAST & AFRICA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 51. UNITED KINGDOM TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 52. UNITED KINGDOM TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 53. UNITED KINGDOM TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
TABLE 54. UNITED KINGDOM TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 55. GERMANY TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 56. GERMANY TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 57. GERMANY TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
TABLE 58. GERMANY TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 59. FRANCE TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 60. FRANCE TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 61. FRANCE TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
TABLE 62. FRANCE TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 63. RUSSIA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 64. RUSSIA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 65. RUSSIA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
TABLE 66. RUSSIA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 67. ITALY TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 68. ITALY TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 69. ITALY TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
TABLE 70. ITALY TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 71. SPAIN TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 72. SPAIN TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 73. SPAIN TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
TABLE 74. SPAIN TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 75. UNITED ARAB EMIRATES TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 76. UNITED ARAB EMIRATES TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 77. UNITED ARAB EMIRATES TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
TABLE 78. UNITED ARAB EMIRATES TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 79. SAUDI ARABIA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 80. SAUDI ARABIA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 81. SAUDI ARABIA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
TABLE 82. SAUDI ARABIA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 83. SOUTH AFRICA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 84. SOUTH AFRICA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 85. SOUTH AFRICA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
TABLE 86. SOUTH AFRICA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 87. DENMARK TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 88. DENMARK TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 89. DENMARK TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
TABLE 90. DENMARK TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 91. NETHERLANDS TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 92. NETHERLANDS TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 93. NETHERLANDS TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
TABLE 94. NETHERLANDS TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 95. QATAR TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 96. QATAR TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 97. QATAR TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
TABLE 98. QATAR TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 99. FINLAND TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 100. FINLAND TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 101. FINLAND TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
TABLE 102. FINLAND TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 103. SWEDEN TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 104. SWEDEN TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 105. SWEDEN TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
TABLE 106. SWEDEN TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 107. NIGERIA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 108. NIGERIA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 109. NIGERIA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
TABLE 110. NIGERIA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 111. EGYPT TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 112. EGYPT TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 113. EGYPT TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
TABLE 114. EGYPT TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 115. TURKEY TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 116. TURKEY TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 117. TURKEY TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
TABLE 118. TURKEY TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 119. ISRAEL TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 120. ISRAEL TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 121. ISRAEL TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
TABLE 122. ISRAEL TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 123. NORWAY TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 124. NORWAY TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 125. NORWAY TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
TABLE 126. NORWAY TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 127. POLAND TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 128. POLAND TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 129. POLAND TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
TABLE 130. POLAND TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 131. SWITZERLAND TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 132. SWITZERLAND TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 133. SWITZERLAND TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
TABLE 134. SWITZERLAND TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 135. ASIA-PACIFIC TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 136. ASIA-PACIFIC TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 137. ASIA-PACIFIC TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
TABLE 138. ASIA-PACIFIC TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 139. ASIA-PACIFIC TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 140. CHINA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 141. CHINA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 142. CHINA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
TABLE 143. CHINA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 144. INDIA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 145. INDIA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 146. INDIA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
TABLE 147. INDIA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 148. JAPAN TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 149. JAPAN TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 150. JAPAN TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
TABLE 151. JAPAN TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 152. AUSTRALIA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 153. AUSTRALIA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 154. AUSTRALIA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
TABLE 155. AUSTRALIA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 156. SOUTH KOREA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 157. SOUTH KOREA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 158. SOUTH KOREA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
TABLE 159. SOUTH KOREA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 160. INDONESIA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 161. INDONESIA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 162. INDONESIA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
TABLE 163. INDONESIA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 164. THAILAND TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 165. THAILAND TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 166. THAILAND TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
TABLE 167. THAILAND TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 168. PHILIPPINES TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 169. PHILIPPINES TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 170. PHILIPPINES TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
TABLE 171. PHILIPPINES TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 172. MALAYSIA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 173. MALAYSIA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 174. MALAYSIA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
TABLE 175. MALAYSIA TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 176. SINGAPORE TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 177. SINGAPORE TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 178. SINGAPORE TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
TABLE 179. SINGAPORE TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 180. VIETNAM TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 181. VIETNAM TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 182. VIETNAM TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
TABLE 183. VIETNAM TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 184. TAIWAN TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 185. TAIWAN TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 186. TAIWAN TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY PROCEDURE TYPE, 2018-2030 (USD MILLION)
TABLE 187. TAIWAN TRANSARTERIAL CHEMOEMBOLIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 188. TRANSARTERIAL CHEMOEMBOLIZATION MARKET SHARE, BY KEY PLAYER, 2024
TABLE 189. TRANSARTERIAL CHEMOEMBOLIZATION MARKET, FPNV POSITIONING MATRIX, 2024

Samples

Sample File DOWNLOAD NOW

Companies Mentioned

The companies profiled in this Transarterial Chemoembolization market report include:
  • AdvaCare Pharma
  • Cadila Healthcare Limited
  • Dr. Reddy’s Laboratories Ltd.
  • Johnson & Johnson Services, Inc.
  • LGM Pharma
  • MicroBiopharm Japan Co., Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Veranova, L.P.
  • WG Critical Care, LLC

Table Information

Report AttributeDetails
No. of Pages197
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.66 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.2 Billion
Compound Annual Growth Rate5.7%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Insight, 2025 - Product Image

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Insight, 2025

  • Clinical Trials
  • 180 Pages
  • Global
From
EUR$2,500USDGBP
Unresectable Hepatocellular Carcinoma - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) - Product Image

Unresectable Hepatocellular Carcinoma - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

  • Report
  • 129 Pages
  • Global
From
EUR$4,750USDGBP
Metastatic Hepatocellular Carcinoma- Pipeline Insight, 2025 - Product Image

Metastatic Hepatocellular Carcinoma- Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
EUR$2,000USDGBP
Unresectable Hepatocellular Carcinoma Market by Therapy Type, Mechanism Of Action, Line Of Therapy, Formulation, Distribution Channel, End User - Global Forecast to 2030 - Product Image

Unresectable Hepatocellular Carcinoma Market by Therapy Type, Mechanism Of Action, Line Of Therapy, Formulation, Distribution Channel, End User - Global Forecast to 2030

  • Report
  • 192 Pages
  • Global
From
EUR$3,545USDGBP
EUR$3,939USDGBP
Copyright © 2002-2025 Research and Markets. All Rights Reserved.
This website uses cookies to ensure you get the best experience. Learn more